scispace - formally typeset
T

Thereasa A. Rich

Researcher at University of Texas MD Anderson Cancer Center

Publications -  61
Citations -  3263

Thereasa A. Rich is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Pheochromocytoma & Paraganglioma. The author has an hindex of 24, co-authored 56 publications receiving 2993 citations. Previous affiliations of Thereasa A. Rich include Washington University in St. Louis & University of Texas Health Science Center at Houston.

Papers
More filters
Journal ArticleDOI

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.

TL;DR: Delivery of preoperative and postoperative chemoradiation in patients who underwent potentially curative pancreaticoduodenectomy for adenocarcinoma of the pancreatic head resulted in similar treatment toxicity, patterns of tumor recurrence, and survival.

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas

TL;DR: In this article, the effects of preoperative versus postoperative fluorouracil (5-FU)-based chemotherapy and irradiation on treatment toxicity, duration of treatment, tumor recurrence, and survival were compared in patients who underwent potentially curative therapy for adenocarcinoma of the pancreatic head during a 5-year period.
Journal ArticleDOI

A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma.

TL;DR: Although PHEO/PGL are rarely diagnosed during childhood, the pediatric provider should be able to recognize and screen for such tumors, particularly in the context of a known genetic predisposition.
Journal ArticleDOI

Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma

TL;DR: An updated review of the clinical and genetic predictors of malignant disease, radiographic diagnosis, and information from the most relevant studies of systemic therapies, as well as proposed treatment guidelines for patients with metastatic or potentially malignant PHs and SPGs are provided.